GlobeNewswire

Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2026
04/11/2026
BANNOCKBURN, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference
04/11/2026
BERKELEY HEIGHTS, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced [...]
Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
04/11/2026
CORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
04/11/2026
In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. The Company’s lead [...]
BioCryst Reports Third Quarter 2026 Financial Results
04/11/2026
— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue [...]
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
04/11/2026
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor $ [...]
Biora Therapeutics Receives Approval for First-in-Human Trial of BioJet™ Oral Biologic Delivery Capsule
04/11/2026
Company remains on track to initiate clinical study evaluating oral, needle-free delivery of adalimumab in December 2026 with data expected in early 2027 SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biora Therapeutics, [...]
Verano Expands Florida Retail Footprint to 87 Locations with Grand Opening of MÜV Fernandina Beach, the Company’s 164th Dispensary Nationwide
04/11/2026
Situated on the scenic Amelia Island in Florida’s Nassau County, MÜV Fernandina Beach is located at 1940 S 8 th Street, a busy thoroughfare that averages a daily traffic count of 20,100 vehicles daily 1 MÜV Fernandina [...]
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
04/11/2026
Conference Call and Webcast Today at 8:30 a.m. ET Received Provisional Approval and Priority Designation for OCU400 in The Bahamas Executed agreement with local partner Global Alliance for Regenerative Medicine (GARM) [...]
Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
04/11/2026
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to [...]
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
04/11/2026
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label long-term safety trial expected in 4Q [...]
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
04/11/2026
Clinical data demonstrate target engagement and support the potential for BH-30236 to address therapeutic resistance in relapsed/refractory AML and HR-MDS SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- BlossomHill [...]
Biodesix to Participate in Upcoming Investor Conferences
04/11/2026
LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present at two upcoming [...]
Neuronetics Reports Third Quarter 2026 Financial and Operating Results
04/11/2026
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient [...]
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
04/11/2026
WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B Repeated Once-Daily Dosing with BP-205 in Multiple-Ascending [...]
MediPharm Labs Appoints Greg Hunter as Chief Executive Officer and Director
04/11/2026
Appointment reflects the Board’s confidence in Mr. Hunter’s proven leadership and strengthens MediPharm’s focus on profitable growth, operational excellence and long-term value creation TORONTO, Nov. 04, 2026 (GLOBE [...]
Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
04/11/2026
HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will [...]
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
04/11/2026
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
04/11/2026
Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives First national CNSide payer agreement to include both tumor cell enumeration and molecular [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum